Drug Trial Radar · NCT04335604
A Study of NOV140201 (JPI-547) in Subject With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jun 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
62
Actual
Start
Dec 6, 2017
Primary completion
Dec 14, 2021
Study completion Dec 14, 2021
Sponsor
- Lead sponsor
- Onconic Therapeutics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Jeil Pharmaceutical Co., Ltd.
- First posted
- Apr 6, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the Safety, Tolerability, and Pharmacokinetic-pharmacodynamic Profile and efficacy of JPI-547 in patients with advanced solid tumor.
Conditions
- Advanced Solid Tumors
Interventions
JPI-547Drug
The dose levels will be escalated following a 3+3 dose escalation scheme.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT) and Maximum tolerated dose (MTD)Time frame: 21days
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Seoul National University College of Medicine
Seoul, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.